Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial

Praxis said elsunersen demonstrated a placebo-adjusted seizure reduction from baseline of 77% (p=0.015) in pediatric patients with SCN2A developmental and epileptic encephalopathy.